© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Denise A. Yardley, MD, from Sarah Cannon Research Institute, discusses toxicities associated with treatment with PI3K inhibitors for breast cancer.
Denise A. Yardley, MD, from Sarah Cannon Research Institute, discusses toxicities associated with treatment with PI3K inhibitors for breast cancer.
<<<